PEN Penumbra Inc
Surgical & Medical Instruments & Apparatus · NYSE · SEC CIK 1321732 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY17.0%
TTM net income YoY-4.3%
TTM EPS YoY-5.3%
Revenue 3-yr CAGR16.2%
Net income 3-yr CAGR56.9%
Margins
Gross margin68.0%
Operating margin12.1%
Net margin10.1%
FCF margin12.8%
EBITDA margin13.4%
Returns
ROE10.7%
ROA8.3%
ROIC (approx.)12.1%
Asset turnover0.83x
Leverage & solvency
Liabilities / assets21.8%
Debt / equity0.00x
Current ratio5.89x
Interest coverage149.48x
Cash quality & payout
Operating cash flow / net income1.66x
Accruals ratio-5.5%
Payout ratio—
Capex / revenue3.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $1.40B | $1.19B | $1.06B | $847.13M | $747.59M |
| Cost of revenue | $461.23M | $439.62M | $375.88M | $311.93M | $272.21M |
| Gross profit | $942.44M | $755.00M | $682.64M | $535.21M | $475.38M |
| R&D expense | $89.77M | $94.78M | $84.42M | $79.41M | $104.55M |
| SG&A expense | $663.42M | $573.99M | $506.45M | $449.72M | $378.33M |
| Operating income | $189.25M | $9.28M | $73.55M | $6.08M | -$7.50M |
| Interest expense | $1.31M | $1.42M | $1.74M | $1.75M | $1.93M |
| Pretax income | $205.12M | $20.87M | $79.65M | $3.89M | -$10.50M |
| Income tax | $27.44M | $6.86M | -$11.30M | $5.89M | -$13.12M |
| Net income | $177.69M | $14.01M | $90.95M | -$2.00M | $5.28M |
| EBITDA | $206.72M | $32.98M | $100.81M | $30.40M | $8.91M |
| EPS (basic) | 4.57 | 0.36 | 2.37 | -0.05 | 0.14 |
| EPS (diluted) | 4.52 | 0.36 | 2.32 | -0.05 | 0.14 |
| Weighted avg. shares (diluted) | 39.29M | 39.27M | 39.22M | 37.84M | 37.88M |
| Balance sheet | |||||
| Cash & equivalents | $186.90M | $324.40M | $167.49M | $69.86M | $59.38M |
| Short-term investments | $357.92M | $15.73M | $121.70M | $118.17M | $195.50M |
| Receivables | $190.02M | $167.67M | $201.77M | $203.38M | $133.94M |
| Inventory | $431.55M | $406.74M | $388.02M | $334.01M | $263.50M |
| Current assets | $1.22B | $951.12M | $915.40M | $755.70M | $681.47M |
| PP&E, net | $117.44M | $62.64M | $72.69M | $65.02M | $58.86M |
| Goodwill | $166.75M | $165.83M | $166.27M | $166.05M | $166.39M |
| Intangibles | $6.19M | $6.51M | $71.06M | $81.16M | $90.62M |
| Total assets | $1.83B | $1.53B | $1.56B | $1.37B | $1.24B |
| Current liabilities | $183.13M | $158.34M | $151.14M | $144.93M | $123.20M |
| Total liabilities | $398.92M | $382.25M | $377.36M | $372.03M | $290.32M |
| Shareholders' equity | $1.43B | $1.15B | $1.18B | $998.86M | $953.93M |
| Shares outstanding | 39.23M | 38.49M | 38.68M | 38.11M | 37.58M |
| Cash flow statement | |||||
| Operating cash flow | $238.66M | $168.48M | $97.33M | -$55.66M | $9.50M |
| Capital expenditure | $63.73M | $21.18M | $15.21M | $19.30M | $21.18M |
| Free cash flow | $174.93M | $147.30M | $82.12M | -$74.96M | -$11.68M |
| Investing cash flow | -$404.59M | $77.62M | -$16.08M | $54.79M | -$21.73M |
| Financing cash flow | $26.53M | -$87.01M | $16.20M | $11.62M | $836,000 |
| Depreciation & amortization | $17.47M | $23.70M | $27.26M | $24.32M | $16.41M |
| Stock-based compensation | $59.21M | $46.16M | $50.52M | $37.38M | $65.76M |
| Share buybacks | $0 | $100.39M | $0 | $0 | — |
Free plan shows the latest 5 periods; Pro shows all 13 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.